Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology
2021/02/14 by Nicholas J. Ashton, Tharick A. Pascoal, Thomas K. Karikari +14 · 39 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Alzheimer's disease research and treatments #Dementia and Cognitive Impairment Research #Amyloidosis: Diagnosis, Treatment, Outcomes
paper · pdf · doi:10.1007/s00401-021-02275-6
Abstract
Abstract The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or plasma, has shown great promise in detecting Alzheimer’s disease (AD) pathophysiology. Tau phosphorylated at threonine 231 (p-tau231) is one such biomarker in CSF but its usefulness as a blood biomarker is currently unknown. Here, we developed an ultrasensitive Single molecule array (Simoa) for the quantification of plasma p-tau231 which was validated in four independent cohorts ( n = 588) in different settings, including the full AD continuum and non-AD neurodegenerative disorders. Plasma p-tau231 was able to identify patients with AD and differentiate them from amyloid-β negative cognitively unimpaired (CU) older adults with high accuracy (AUC = 0.92–0.94). Plasma p-tau231 also distinguished AD patients from patients with non-AD neurodegenerative disorders (AUC = 0.93), as well as from amyloid-β negative MCI patients (AUC = 0.89). In a neuropathology cohort, plasma p-tau231 in samples taken on avergae 4.2 years prior to post-mortem very accurately identified AD neuropathology in comparison to non-AD neurodegenerative disorders (AUC = 0.99), this is despite all patients being given an AD dementia diagnosis during life. Plasma p-tau231 was highly correlated with CSF p-tau231, tau pathology as assessed by [ 18 F]MK-6240 positron emission tomography (PET), and brain amyloidosis by [ 18 F]AZD469 PET. Remarkably, the inflection point of plasma p-tau231, increasing as a function of continuous [ 18 F]AZD469 amyloid-β PET standardized uptake value ratio, was shown to be earlier than standard thresholds of amyloid-β PET positivity and the increase of plasma p-tau181. Furthermore, plasma p-tau231 was significantly increased in amyloid-β PET quartiles 2–4, whereas CSF p-tau217 and plasma p-tau181 increased only at quartiles 3–4 and 4, respectively. Finally, plasma p-tau231 differentiated individuals across the entire Braak stage spectrum, including Braak staging from Braak 0 through Braak I–II, which was not observed for plasma p-tau181. To conclude, this novel plasma p-tau231 assay identifies the clinical stages of AD and neuropathology equally well as plasma p-tau181, but increases earlier, already with subtle amyloid-β deposition, prior to the threshold for amyloid-β PET positivity has been attained, and also in response to early brain tau deposition. Thus, plasma p-tau231 is a promising novel biomarker of emerging AD pathology with the potential to facilitate clinical trials to identify vulnerable populations below PET threshold of amyloid-β positivity or apparent entorhinal tau deposition.
Cited by
- Biological functions of the m6A reader YTHDF2 and its role in central nervous system disorders
- Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
- Enhancing diagnostic precision in Alzheimer's disease: Impact of comorbidities on blood biomarkers for clinical integration
- Plasma p‐tau immunoassays in clinical research for Alzheimer's disease
- Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data
- Detecting amyloid–β pathology in subjective cognitive decline using plasma and CSF biomarkers
- Plasma p-tau217 and glucose metabolism correlate in neocortical association areas in Alzheimer's disease
- Tau in cerebrospinal fluid induces neuronal hyperexcitability and alters hippocampal theta oscillations
- Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease
- Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer’s disease neuropathology
- Tau pathology in epilepsy: emerging mechanisms and translational opportunities
- Prediction of continuous amyloid positron emission tomography with fluid measures of phosphorylated tau and β-amyloid
- Nucleic acid aptamer-based electrochemical sensor for the detection of serum P-tau231 and the instant screening test of Alzheimer’s disease
- Association between blood-based protein biomarkers and brain MRI in the Alzheimer’s disease continuum: a systematic review
- A multicentre validation study of the diagnostic value of plasma neurofilament light. [europepmc]
- Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. [europepmc]
- Neurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies. [europepmc]
- Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. [europepmc]
- Blood-based biomarkers for Alzheimer's disease. [europepmc]
- Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. [europepmc]
- Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy. [europepmc]
- Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. [europepmc]
- Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change. [europepmc]
- Advances in the development of new biomarkers for Alzheimer's disease. [europepmc]
- Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5-90 years. [europepmc]
- The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. [europepmc]
- Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease. [europepmc]
- Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias. [europepmc]
- Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays. [europepmc]
- Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring. [europepmc]
- Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. [europepmc]
- Plasma phospho-tau in Alzheimer's disease: towards diagnostic and therapeutic trial applications. [europepmc]
- Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease. [europepmc]
- Designing the next-generation clinical care pathway for Alzheimer's disease. [europepmc]
- Biomarker modeling of Alzheimer's disease using PET-based Braak staging. [europepmc]
- Blood biomarkers for Alzheimer's disease in clinical practice and trials. [europepmc]
- Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape. [europepmc]
- A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases. [europepmc]
- Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. [europepmc]
Related